US FDA approved MenQuadfi, the first quadrivalent meningococcal vaccine aged two years and above.
The vaccine uses tetanus toxoid as a protein carrier and formulated as a ready-to-use liquid product. Sanofi Pasteur executive vice-president David Loew said, “Meningococcal meningitis remains a major global health challenge because it can strike quickly and with devastating effect, taking a life in less than 24 hours”. This vaccine has the ability to help prevent this disease through vaccination next year.